Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer | Access and Reimbursement | Realizing the Potential of Personalized Medicine in Oncology | US | 2016
Biomarker-driven prescribing plays an increasingly prominent role in key oncology indications. The choice of therapy for breast cancer has long been informed by the presence of key biomarkers, and…
Breast Cancer, Colorectal Cancer, Non-Small-Cell Lung Cancer | Access and Reimbursement | Biomarkers in Oncology | China | 2016
Introduction Oncology is increasingly moving toward a personalized treatment approach, enlisting predictive biomarkers to guide therapy choice. This trend is already being felt in indications as…
Breast Cancer | Access and Reimbursement |The Escalating Cost of Treating HR-Positive/HER2-Negative Breast Cancer | US | 2016
Owing to the large size of the advanced/metastatic, HR-positive/HER2-negative breast cancer market, as well as the long durations of treatment typically associated with treating these patients,…
Breast Cancer | Emerging Therapies | Ibrance (palbociclib) | US | Wave 2 | 2015
LaunchTrends: Ibrance (Wave 2) is the second in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched breast cancer…
Breast Cancer (Advanced/Metastatic, HR-Positive, HER2-Negative) | Decision Base | US | 2015
Which Attributes, in the Eyes of Oncologists and Payers, Will Allow Emerging Therapies to Gain Traction in a Market Experiencing Generic Erosion? Drug development for advanced/metastatic,…
